Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 171 in Subjects With Obesity
NCT04199351Phase 1Terminated
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 171 in obesity, sponsored by Amgen. Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2019; status: terminated.
02
Drugs
AMG 171
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04199351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199351.